BMI View: Macroeconomic and political instability throughout Latin America continue to pose downsiderisks for drugmaker revenues as access to pharmaceuticals and healthcare remains a concern. Despite this,the Latin America region's high demand for medicines and regulatory advancements will maintaindrugmaker interest in the long term.
Headline Expenditure Projections
Pharmaceuticals: USD57.5bn in 2016 to USD63.3bn in 2017; 10.0% in US dollar terms.
Healthcare: USD363.6bn in 2016 to USD404.8bn in 2017; 11.3% in US dollar terms.
The Americas region will remain characterised by highly divergent levels of attractiveness for innovativepharmaceutical firms. While North America presents considerable opportunities for the commercialisationof pharmaceuticals, it is vital that companies appreciate the varying levels of investment risks and rewardsthat are present in the emerging markets of Latin America. BMI's Innovative Pharmaceuticals Risk/RewardIndex tool, which provides a globally comparative and numerically based assessment of a market'sattractiveness for companies looking to launch a high-value drug, was established to address this.